Annual report for Marksans Pharma Ltd. for FY-2019
29-05-2019
Marksans Pharma Ltd - 524404 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report27/05/2019 3 Name of the Certifying Firm Jinesh Dedhia & Associates 4 Name of the Certifying Individual Jinesh Dedhia 5Membership TypeACS 6 Membership Number 54731 7 CP No. 20229 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO28-05-2019
Marksans Pharma Ltd - 524404 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayMARKSANS PHARMA LTD. 2CINL24110MH1992PLC066364 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 77.76 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harshavardhan Panigrahi Designation: Company Secretary EmailId: harshavardhan@marksanspharma.com Name of the Chief Financial Officer: Jitendra Sharma Designation: Chief Financial Officer EmailId: jitendra@marksanspharma.com Date: 23/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.23-05-2019
MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for To Consider And Approve The Annual Audited Financial Results Of The Company (Both Standalone And Consolidated) For The Financial Year Ended 31St March, 2019. The Board Of Directors Will Also Consider Recommendation Of Dividend, If Any, For The Financial Year 2018-19.
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2019 ,inter alia, to consider and approve This is to inform you that the Meeting of the Board of Directors of the Company will be held on Wednesday, 29th May, 2019 at Mumbai, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended 31st March, 2019. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2018-19. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares is closed for the Company's insiders from 3rd April, 2019 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 29th May, 2019.20-05-2019
Marksans Pharma Ltd - 524404 - Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018.
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Dear Sir, Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2019 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company.02-05-2019
Marksans Pharma Ltd - 524404 - Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir, With reference to above captioned subject, please find enclosed half yearly Compliance Certificate pursuant to Regulation 40 (9) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This information pertains to half year ended March 31, 2019.22-04-2019
Marksans Pharma Ltd - 524404 - Shareholding for the Period Ended March 31, 2019
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here16-04-2019
MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer11-04-2019
Marksans Pharma Ltd - 524404 - Compliance Certificate For The Period Ended 31St March, 2019
Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.04-04-2019
MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading)(Amendment) Regulations, 2018 and as per the clarification received from BSE and NSE vide their letters dated 2nd April, 2019, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) will remain closed with immediate effect (i.e. 3rd April, 2019) till 48 hours after the declaration of financial results for the quarter and year ended 31st March, 2019. The date of declaration of financial results will be intimated separately in due course of time. Employees of the Company and/or their immediate relatives shall not trade in the securities of the Company during the aforesaid period of closure of trading window.03-04-2019